Intracellular fat deposition



Similar documents
New Approaches to Treating Fatty Liver Disease. Mack C. Mitchell, MD University of Texas Southwestern Medical Center Dallas, Texas

NASH: It is not JUST a Fatty Liver. Karen F. Murray, M.D. Director of Hepatobiliary Program Children s Hospital and Regional Medical Center

Non-alcoholic fatty liver disease: Prognosis and Treatment

THE ENDOCANNABINOID SYSTEM AS A THERAPEUTIC TARGET FOR LIVER DISEASES. Key Points

SHAHID AZIZ DO, FACOI.

Abnormal Liver Function. Dr William Alazawi MA(Cantab) PhD MRCP Senior Lecturer and Consultant in Hepatology Queen Mary, University of London

Alcohol and the Liver

Body Composition & Longevity. Ohan Karatoprak, MD, AAFP Clinical Assistant Professor, UMDNJ

BACKGROUND MEDIA INFORMATION Fast facts about liver disease

Epidemiology of Hypertension 陈 奕 希 李 禾 园 王 卓

Role of Body Weight Reduction in Obesity-Associated Co-Morbidities

Liver, Gallbladder, Exocrine Pancreas KNH 406

Liver Transplantation for Hepatocellular Carcinoma. John P. Roberts, MD Chief, Division of Transplant Service University of California, San Francisco

Primary Care Guidance Program: Non-Alcohol related Fatty Liver Disease (NAFLD) Guidance on Management in Primary Care

Insulin Receptor Substrate 1 (IRS1) Gene Variation Modifies Insulin Resistance Response to Weight-loss Diets in A Two-year Randomized Trial

Give a NOD to diabetes:

THE FAT YOU CAN T SEE

Η δίαιτα στην πρόληψη του αγγειακού εγκεφαλικού επεισοδίου

Steatosi, infiammazione e fibrosi: meccanismi patogenetici e interazioni

Non-Alcoholic Fatty Liver Disease

Fewer people with coronary heart disease are being diagnosed as compared to the expected figures.

Alcoholic Liver Disease in Women

MANAGEMENT OF LIVER CIRRHOSIS

Diabetes and Obesity in Children. Janie Berquist, RN, BSN, MPH, CDE Children s Mercy Hospitals and Clinics Kansas City, MO

Metabolic Syndrome Overview: Easy Living, Bitter Harvest. Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007

Appendix: Description of the DIETRON model

ALPHA (TNFa) IN OBESITY

CORPORATE HEALTH LOWERING YOUR CHOLESTEROL & BLOOD PRESSURE

Introduction. Pathogenesis of type 2 diabetes

JESSE HUANG ( 黄 建 始 ),MD,MHPE,MPH,MBA Professor of Epidemiology Assistant President

ELEMENTS FOR A PUBLIC SUMMARY. Overview of disease epidemiology. Summary of treatment benefits

Nonalcoholic Fatty Liver Disease. Dietary and Lifestyle Guidelines

Diabetes and Stroke. Understanding the connection between diabetes and the increased risk of stroke

Non Alcoholic Steato-Hepatitis (NASH)

Heritability: Twin Studies. Twin studies are often used to assess genetic effects on variation in a trait

Cardiovascular Disease Risk Factors

Risk Factors for Alcoholism among Taiwanese Aborigines

1. PATHOPHYSIOLOGY OF METABOLIC SYNDROME

Psoriasis Co-morbidities: Changing Clinical Practice. Theresa Schroeder Devere, MD Assistant Professor, OHSU Dermatology. Psoriatic Arthritis

The Polyphenol Study. Effect of Dietary Polyphenols on Intestinal Microbiota, Intestinal Inflammation and Metabolic Syndrome

Diabetes and Obesity. The diabesity epidemic

Boehringer Ingelheim- sponsored Satellite Symposium. HCV Beyond the Liver

NP/PA Clinical Hepatology Fellowship Summary of Year-Long Curriculum

Do You Know the Health Risks of Being Overweight?

inflammation of the pancreas and damage to the an increased risk of hypertension, stroke and Table 7.1: Classification of alcohol consumption

How To Treat Dyslipidemia

Type 2 Diabetes and Prediabetes: A New Understanding of Cause and Treatment. Bruce Latham, M.D. Endocrine Specialists Greenville Health System

Blood clot in atheroma. help make vitamin D and hormones, like oestrogen and testosterone, in your body.

Dietary Composition for Weight Loss and Weight Loss Maintenance

Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review

Diabetes and Heart Disease

High Blood Cholesterol

Stroke: Major Public Health Burden. Stroke: Major Public Health Burden. Stroke: Major Public Health Burden 5/21/2012

Vitamin D und seine Bedeutung im Immunsystem und bei der Infektabwehr

Why are some drugs only available on prescription? Depressants. Pain killers. Stimulants. Performance enhancers. Hallucinogens

Why is HDL Cholesterol Low in People with Insulin Resistance and Type 2 Diabetes Mellitus?

Drugs and Alcohol in Primary Care Steve Brinksman Clinical Lead SMMGP

Subproject 4: Specification and Documentation of Metabolic and Neoplastic Diseases

Draft comprehensive global monitoring framework and targets for the prevention and control of noncommunicable diseases

The relationship between socioeconomic status and healthy behaviors: A mediational analysis. Jenn Risch Ashley Papoy.

ALCO H O L AN D H EALTH THE EFFECTS OF MODERATE, REGULAR ALCOHOL CONSUMPTION

PREVENTION OF HCC BY HEPATITIS C TREATMENT. Morris Sherman University of Toronto

Healthy life resources for the cancer community. Tonight: Healthy Eating with Diane B. Wilson, EdD, RD. January 18, 2012

Nutrition for Family Living

Margarines and Heart Disease. Do they protect?

Dietary Fiber and Alcohol. Nana Gletsu Miller, PhD Spring 2014

Using Family History to Improve Your Health Web Quest Abstract

DIABETES AND INSULIN RESISTANCE DIABETES PREVALANCE

Social inequalities in all cause and cause specific mortality in a country of the African region

Kansas Behavioral Health Risk Bulletin

Isagenix Clinical Research Summary Suk Cho, Ph.D., Eric Gumpricht, Ph.D., David Despain, M.Sc.

DISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD

Family History and Diabetes. Practical Genomics for the Public Health Professional

What to Do with the Patient With Abnormal Liver Enzymes? Nizar N. Zein, M.D. The Cleveland Clinic

Validation and Replication

Non-alcoholic Fatty Liver Disease (NAFLD): Does Anything Help?

Brochure More information from

Big Data for Population Health and Personalised Medicine through EMR Linkages

Overview and update of modern type 2 Diabetes philosophy and management. Dr Steve Stanaway Consultant Endocrinologist BCU

Alcohol: The good, the bad and

Fat and Viral Liver Disease

Transcription:

Who Gets Alcoholic Liver Disease? Chris Day Newcastle University

Alcoholic Fatty Liver (Steatosis) Fatty hepatocytes Intracellular fat deposition

Alcoholic SteatoHepatitis (ASH) Fat deposits Inflammation Fibrosis with necrosis

Cirrhosis Cirrhosis Regenerative nodule Fibrosis Nodules surrounded by fibrosis

Normal (0-30%) Fatty Liver (60-100%) Prevalence of disease stages in unselected heavy drinkers WHY?? Steatohepatitis (20-30%) Cirrhosis (<10%)

Non-genetic (inherited) factors Dose & pattern of alcohol intake Dietary factors Specific nutrients? General excess (obesity) Smoking Becker 2002, Klatsky 2006 Coffee drinking Gut bacteria (the microbiome )? Klatsky 2006

ALD & Dose: population level Cirrhosis death rate correlates with per capita alcohol intake Leon et al Lancet 2006

ALD & Dose: individual level % of category 8 7 6 5 4 3 2 1 0 0 0.1-3 3-6 6-9 9-12 >12 Drinks per day Cirrhosis Any liver disease Bellentani et al 1997

ALD risk and pattern of intake Risk of ALD increased by: Drinking outside meal-times Risk : 3.4[1.7-6.6] Bellentani 1997 Drinking beer/spirits rather than wine Risk : 2.5[1.7-3.3] Becker 2002 Daily versus weekend drinking Risk : 2.5 [1.8-4.6] Stokkeland 2008

Is wine vs beer effect due to confounding lifestyle factors? Johansen, Friis, Skovenborg, Gronbaek BMJ 2006

Diet and ALD: the role of obesity % overweight 35 30 25 20 15 10 5 0 With lesion Without lesion Steatosis Hepatitis Cirrhosis 1604 heavy drinkers Overweight = minimum BMI>25 women, >27 men in previous 10yr In multivariate analysis obesity/glucose best predictors of cirrhosis (Risk > x 2 for obesity) Naveau et al 1997 Raynard et al 2002

Rates of liver cirrhosis in 1,230,662 UK women (mean age 56yrs) followed up for mean 6.2 years Liu Br Med J 2010

Relative risks of contributions of BMI and alcohol to liver disease mortality (adjusted for all risk factors). 9,559 Scottish men followed up for mean 29 years Hart Br Med J 2010

Obesity & ALD:?explanation for association Mechanisms of ALD & obesity related liver disease (NAFLD) very similar: Metabolic overload Oxidative, ER and cytokine mediated stress The microbiome/endotoxinendotoxin Direct fibrogenic (scar producing) effects of obesity High Insulin/glucose Adipokine profile

Risk of ALD and coffee drinking Coffee intake Relative Risk of ALD Never/seldom 1.0 <1 0.7 [0.4-1.1] 1-3 0.6[0.4-0.8], 0.8], p<0.001 4 0.2[0.1-0.4], 0.4], p<0.001 Per cup/day 0.8[0.7-0.9], 0.9], p<0.001 Adjusted for age, weight, smoking, gender, ethnicity Klatsky 2006

Gut bacteria - the microbiome - and ALD susceptibility? Abundant evidence that the gut microbiome may be involved in ALD pathogenesis Purohit 2008 Non-alcoholic steatohepatitis (NASH) as a transmissible disease? What about ALD? Henao-Mejia Nature 2012 Faeces from ALD patients induce ALD in alcohol fed mice Llopis 2013

Tilg & Day Nat Clin Practice 2007

Gender and ALD Females develop ALD at lower intake Explanation: blood alcohol levels for same dose per body weight Vol distribution Marshall 1983 Estrogen sensitises the liver (Kupffer cells) to bacterial (endo) toxins gut permeability to endotoxin Endotoxin receptors (CD14) & release of inflammatory mediators from liver inflammatory cells (eg. TNFa) Thurman et al 1999

Tilg & Day Nat Clin Practice 2007

Are genes important? Concordance rates (%) among 15 924 male twin pairs age 67-77. Alcoholism and cirrhosis 25%. MZ DZ 1981 1996 MZ DZ Ethnic variation in susceptibility Caetano & Clark 1998, Stinson 2001, Klatsky 2006 Alcoholism 26.3 11.9 Cirrhosis 14.6 5.4 Alcoholism 26.7 12.2 Cirrhosis 16.9 5.3 Alcoholism genetic ALD genetic Risk over-and-above the risk of alcoholism Hrubec 1981 Alcoholism genetic ALD risk now shared with alcoholism No longer a significant independent genetic risk for ALD Reed 1996

Finding the genes Hypothesis-driven Candidate gene case-control control studies All studies in ALD thus far Almost all underpowered (too small) Hypothesis-free (generating) Whole genome scanning None in ALD as yet (underway) BUT: Clues from studies in NAFLD

NIH-PA Author Manuscript NIH-PA NIH-PA Author Manuscript NIH-PA Author Manuscr Romeo et al. USA Study population: (Black n=1032, White n=636, Hispanic n=383). 9229 non-synonymous exonic SNPs. Steatosis defined non-invasively by 1 H-MRS. Romeo et al. PNPLA3 (I148M) Carriage of G allele associated with increased steatosis (p=5.9 x 10-10 )

Presence of NASH OR 1.5 (1.12-2.04) N=591 Fibrosis >F1 OR 1.5 (1.09-2.12)

PNPLA3 - Adiponutrin But why the link with NASH & scarring? He et al, 2010 Huang et al, 2010 Huang et al, 2011 Pirazzi et al, 2012 Anstee et al, 2013

Case control studies of PNPLA3 in ALD Study Numbers Ethnicity Associated phenotype Tian, 2010 1,221 Mexican- European Risk of ALD and cirrhosis Seth, 2010 548 UK Risk of ALD and cirrhosis Stickel, 2010 1,043/376 German Risk of ALD and cirrhosis Trepo, 2011 658 Belgian Risk of ALD and cirrhosis Trepo 2012 571 Belgian and French Risk of HCC Nischalke 2011 160 Germany Risk of HCC

TM6SF2 (E167K) Carriage of minor allele associated with increased steatosis (p=5.7 x 10-8 ) Carriage of major allele increased cholesterol and cardiovascular disease See also: Holmen et al, Nature Genetics, 2014

Nature Communications, 2014; 10.1038/ncomms5309. Multivariate analysis (additive model) incorporating Age, Gender, BMI, T2DM and PNPLA3 rs738409 genotype. i.e. OR per copy of the minor allele carried

Obesity Alcohol T2DM T-allele Lys167 (E167K) Hepatic VLDL Excretion TG LDL-C Intrahepatic Fatty Acid Flux TM6SF2 rs58542926 C-allele Glu167 (E167K) Does TM6SF2 genotype determine the CAUSE of death in NAFLD/ALD? Hepatic VLDL Excretion TG LDL Total Chol IHTG Steatosis? NASH Fibrosis Cardiovascular Disease

TM6SF2 gene variant determines risk of liver and heart disease Dongiovanni 2014

Conclusions ALD is a typical complex disease with susceptibility likely due to a combination of genetic/environmental factors Several modifiable environmental risk factors such as diet/coffee drinking identified Role of the microbiome as a modifiable and?transmissible risk factor worthy of further study PNPLA3 is the only robust genetic association reported thus far and is also associated with HCC Genetic factors may explain CAUSE of death in heavy drinkers Genome wide scans are awaited with interest